Faruqi & Faruqi, LLP
, a leading national securities law firm, is investigating potential claims againstLifecore Biomedical, Inc.
(LFCR). The firm is acting on behalf of investors who may have suffered losses due to alleged misrepresentations and omissions made by the Company and its executives.The investigation stems from a series of disclosures made by Lifecore regarding accounting irregularities. These disclosures, starting in January 2024, revealed that the Company was unable to file its financial reports on time due to ongoing internal control deficiencies and the need to restate previously issued financial statements. These revelations led to a significant decline in Lifecore’s stock price, raising concerns among investors.
Faruqi & Faruqi believes that Lifecore may have violated federal securities laws by making false and misleading statements to the public. The firm alleges that the Company and its executives failed to disclose crucial information about the internal control deficiencies and the need for restatements, potentially misleading investors about Lifecore’s financial position and prospects.
The firm is now urging investors who suffered losses exceeding $75,000 in Lifecore between October 7, 2020, and March 19, 2024, to contact them for a free consultation. They are also actively seeking individuals who may have information regarding Lifecore’s conduct, including whistleblowers, former employees, shareholders, and others.
If you are an investor who suffered losses exceeding $75,000 in Lifecore between October 7, 2020, and March 19, 2024, please contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
For more information on the Lifecore class action, visit the firm’s website at www.faruqilaw.com/LFCR.
